Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR2 | P50052 | 9/20 | 0.70 |
| ▸ | AGTR1 | P30556 | 3/20 | 0.70 |
| ▸ | REN | P00797 | 2/20 | 0.61 |
| ▸ | NPY2R | P49146 | 2/20 | 0.57 |
| ▸ | NPY4R | P50391 | 2/20 | 0.57 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.57 |
| ▸ | NPY1R | P25929 | 1/20 | 0.57 |
| ▸ | RAMP3 | O60896 | 1/20 | 0.57 |
| ▸ | CALCR | P30988 | 1/20 | 0.57 |
| ▸ | FCGRT | P55899 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Angiotensin-Ii SCHEMBL29362121 | 0.97 | AGTR2 (0.76) | AGTR2AGTR1RENNPY2RNPY4R | |
| Angiotensin Amide SCHEMBL5722115 | 0.92 | AGTR2 (0.75) | AGTR2AGTR1RENNPY2RNPY4R | |
| Angiotensin Ii SCHEMBL13232382 | 0.92 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL2566771 | 0.92 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL1189 | 0.92 | AGTR2 (0.84) | AGTR2AGTR1REN | |
| Angiotensin Amide SCHEMBL9324 | 0.91 | AGTR2 (0.74) | AGTR2AGTR1RENNPY2RNPY4R | |
| Angiotensin Amide SCHEMBL8155919 | 0.91 | AGTR2 (0.74) | AGTR2AGTR1RENNPY2RNPY4R | |
| Angiotensin Ii SCHEMBL3465991 | 0.91 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL14990505 | 0.91 | AGTR2 (0.83) | AGTR2AGTR1REN | |
| Angiotensin Ii SCHEMBL21267957 | 0.91 | AGTR2 (0.83) | AGTR2AGTR1REN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 733 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4041275-B1 | TREATMENT AND PREVENTION OF NEPHROTOXIN-INDUCED KIDNEY INJURIES | FARSIGHT MEDICAL TECH SHANGHAI CO LTD (CN) | 2026-05-20 | — | — | EP | claimed |
| EP-3934654-B1 | ISTAROXIME OR ITS METABOLITE PST-3093 FOR USE AS INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE (AHF) | WINDTREE THERAPEUTICS INC (US) | 2026-04-29 | — | — | EP | claimed |
| EP-3746081-B1 | PDE1 INHIBITORS FOR USE TO TREAT CARDIAC FAILURE AND CARDIOTOXICITY | INTRA CELLULAR THERAPIES INC (US) | 2026-04-01 | — | — | EP | claimed |
| EP-4142775-B1 | TREATMENT AND/OR PREVENTION OF A DISEASE OR A SYNDROME RELATED TO A VIRUS INFECTION | Ageronix SA (CH) | 2026-03-25 | — | — | EP | claimed |
| EP-4215194-B1 | COMBINATION THERAPY OF AT1 R BLOCKER AND CCR2 INHIBITOR FOR THE TREATMENT, AMELIORATION OR PREVENTION OF A KIDNEY DISEASE | DIMERIX BIOSCIENCE PTY LTD (AU) | 2026-03-25 | — | — | EP | claimed |
| EP-4076398-B1 | LEVOSIMENDAN FOR TREATING PULMONARY HYPERTENSION WITH HEART FAILURE WITH PRESERVED EJECTION FRACTION (PH-HF-PEF) | TENAX THERAPEUTICS INC (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4043017-B1 | CANCER TREATMENT USING COMBINATIONS OF ERK AND RAF INHIBITORS | BIOMED VALLEY DISCOVERIES INC (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3781315-B1 | MICROFLUIDIC METHOD FOR SINGLE CELL ANALYSIS | HIFIBIO SAS (FR) | 2026-01-14 | — | — | EP | claimed |
| EP-4676563-A1 | DEVICE AND METHOD FOR PURIFYING BODY FLUIDS BY REMOVING ANGIOTENSIN-SPECIFIC ANTIBODIES | Klingenberg, Georg Jochen (DE) | 2026-01-14 | — | — | EP | claimed |
| EP-2916851-B1 | POTASSIUM-BINDING AGENTS FOR TREATING HYPERTENSION AND HYPERKALEMIA | VIFOR INT LTD (CH) | 2025-12-17 | — | — | EP | claimed |
| EP-3043824-B1 | MODIFIED THERAPEUTIC AGENTS AND COMPOSITIONS THEREOF | SCRIPPS RESEARCH INST (US) | 2022-07-06 | — | — | EP | claimed |
| EP-2265207-B1 | SYSTEM AND METHOD FOR INDIRECTLY MEASURING CALCIUM ION EFFLUX | CELTRAST LLC (US) | 2022-06-15 | — | — | EP | claimed |
| EP-3207940-B1 | COMPOSITIONS OF A NEUREGULIN FOR PREVENTING, TREATING OR DELAYING PRESERVED EJECTION FRACTION CARDIAC FAILURE | ZENSUN SHANGHAI SCIENCE & TECH CO LTD (CN) | 2022-06-01 | — | — | EP | claimed |
| EP-3256446-B1 | (2S,4R)-5-(5'-CHLORO-2'-FLUOROBIPHENYL-4-YL)-4-(ETHOXYOXALYLAMINO)-2-HYDROXYMETHYL-2-METHYLPENTANOIC ACID AS NEPRILYSIN INHIBITOR | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-18 | — | — | EP | claimed |
| EP-3099668-B1 | 5-BIPHENYL-4-HETEROARYLCARBONYLAMINO-PENTANOIC ACID DERIVATIVES AS NEPRILYSIN INHIBITORS | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2022-05-04 | — | — | EP | claimed |
| EP-3928763-B1 | TRANSMUCOSAL AND TRANSDERMAL DELIVERY SYSTEMS | MEDLAB CLINICAL U S INC (US) | 2022-05-04 | — | — | EP | claimed |
| EP-3411026-B1 | USE OF STIMULATORS OF SOLUBLE GUANYLATE CYCLASE FOR THE TREATMENT OF NONALCOHOLIC STEATOHEPATITIS (NASH) | CYCLERION THERAPEUTICS INC (US) | 2022-03-09 | — | — | EP | claimed |
| EP-3536685-B1 | BICYCLIC-FUSED HETEROARYL OR ARYL COMPOUNDS AND THEIR USE AS IRAK4 INHIBITORS | PFIZER (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3724336-B1 | IMPROVED COMPOUND FOR TREATMENT OF HEART FAILURE | MEDIZINISCHE HOCHSCHULE HANNOVER (DE) | 2022-02-09 | — | — | EP | claimed |
| EP-3942016-A1 | NOVEL LACTIC ACID BACTERIA STRAINS THAT PROMOTE THE ABSORPTION OF CALCIUM - PEPTIDES AND ASSOCIATED PRODUCTS | VF Bioscience (FR) | 2022-01-26 | — | — | EP | claimed |